GemPharmatech Co

GemPharmatech Co Interest Expense

The Interest Expense of GemPharmatech Co (688046.SS) as of Oct 23, 2026 is 22.13 M CNY. In the previous year, Interest Expense was 28.70 M CNY — a change of -22.91% (lower).

Interest Expense

22.13 MCNY

YoY

-22.91%

Last updated:

Interest Expense of GemPharmatech Co is 2024 22.13 M CNY. Interest Expense of GemPharmatech Co was 2023 28.70 M CNY. It decreases by -22.91% lower compared to the previous year.

The GemPharmatech Co Interest Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Expense
Date
Interest Expense
Jan 1, 2018
68,400.00 CNY
Jan 1, 2019
3.26 M CNY
Jan 1, 2020
6.42 M CNY
Jan 1, 2021
13.61 M CNY
Jan 1, 2022
24.68 M CNY
Jan 1, 2023
28.70 M CNY
Jan 1, 2024
22.13 M CNY
The GemPharmatech Co Interest Expense history
YEARInterest ExpenseYoY
22.13 MCNY-22.91%
28.70 MCNY+16.27%
24.68 MCNY+81.31%
13.61 MCNY+111.99%
6.42 MCNY+97.17%
3.26 MCNY+4,662.13%
68,400.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GemPharmatech Co Stock analysis

What does GemPharmatech Co do? GemPharmatech Co., Ltd. generates revenue through the research and development, manufacturing, and sale of experimental mouse models. The company utilizes gene-editing and other technologies to produce these models, which are primarily sold to satisfy experimental demands in gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental research areas. Customized model breeding, drug efficacy analysis, and model customization services are also key revenue streams, targeting institutions engaged in biomedical research and pharmaceutical development. The company's products and services are tailored for clients in the fields of gene function cognition, disease mechanisms analysis, and drug target discovery. These clients include research institutions and pharmaceutical companies requiring specialized mouse models for preclinical studies and drug development. The firm's focus on gene-editing technologies enables it to provide high-quality, customized solutions that meet specific research needs. GemPharmatech's business model centers on providing innovative solutions for experimental research through its proprietary gene-editing technologies. By offering both standard and customized mouse models alongside related services, the company addresses the growing demand for precise and efficient research tools in the pharmaceutical and biotechnology sectors. The firm's revenue streams are directly tied to the sale of these models and the provision of specialized services to clients in the biomedical research industry. GemPharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GemPharmatech Co stock

Interest Expense of GemPharmatech Co is 22.13 M CNY in 2024.

Interest Expense of GemPharmatech Co changed from 28.70 M CNY to 22.13 M CNY, representing a -22.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Expense GemPharmatech Co since 2006 – with annual values, charts, and detailed analysis.

Interest expense represents the cost of borrowing. Higher interest expenses can indicate a highly leveraged company.

Interest Expense's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Interest Expense's GemPharmatech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — GemPharmatech Co

All Key Metrics — GemPharmatech Co